|Bid||280.00 x 800|
|Ask||283.40 x 800|
|Day's range||281.40 - 286.20|
|52-week range||167.98 - 293.15|
|PE ratio (TTM)||73.74|
|Earnings date||30 Jul 2018 - 3 Aug 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||278.38|
The fast pace of innovation in biotech is the biggest risk to Illumina's future. With a $42 billion market cap, it could sting sooner than investors think.
Anika Therapeutics' (ANIK) shares declined 37%, after the company reported disappointing data from its phase III Cingal 16-02 study in treating patients with osteoarthritis (OA) in the knee.
We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns
Novo Nordisk (NVO) enters into a research collaboration and option agreement with Kallyope, Inc. to develop novel therapies for diabetes and obesity.
Alexion Pharmaceuticals, Inc. (ALXN) submits a Biologics License Application (BLA) to the FDA for approval of ALXN1210 to treat patients with paroxysmal nocturnal hemoglobinuria (PNH).
Walgreens Boots' (WBA) consistent sales rise in the Retail Pharmacy International business is encouraging. Moreover, the company steadily gains traction from a slew of strategic deals.
After considering various parameters and fundamentals, we help you make a choice between Boston Scientific (BSX) and Baxter (BAX).
Agios Pharmaceuticals, Inc. (AGIO), initiates a phase III ACTIVATE study which will evaluateits lead rare genetic diseases candidate, AG-348 in patients with PK deficiency who do not receive regular blood transfusions.
Hologic's (HOLX) receipt of Health Canada approval for the new Panther Fusion system and Panther Fusion assays, for respiratory virus infections, is expected to boost the top line in the near term.
Amedisys' (AMED) solid performance in the recently launched Personal Care segment buoys optimism. A favorable demographic trend and strategic acquisitions also bode well for the company.
Dr. Reddy's (RDY) and Mylan announced that the FDA approved the first generic version of Suboxone (Buprenorphine and Naloxone Sublingual Film) under-the-tongue film for the treatment of opioid addiction.
Flex Pharma (FLKS) announced that the company is ending the phase II studies for its pipeline candidate FLX-787 in two indications. The company also plans to lower its workforce by about 60%.
Roche (RHHBY) announced that the FDA has approved the label expansion for its oncology drug Avastin in combination with chemotherapy, for the treatment of women with advanced ovarian cancer following initial surgical resection.
CVS Health (CVS) significantly advances more than halfway through its 2019 renewals. Also, strong year-over-year Retail/LTC comparisons are encouraging.
Genomic Health (GHDX) gains ground on promising reimbursement prospects for its Oncotype DX breast cancer test and solid international scenario.
Illumina Inc (NASDAQ:ILMN), a large-cap worth US$41.20B, comes to mind for investors seeking a strong and reliable stock investment. Big corporations are much sought after by risk-averse investors who findRead More...
Amedisys (AMED) works on its strategy to deploy capital in an accretive manner, maintaining low leverage and substantial borrowing capacity for future investment.
The gradually stabilizing Cardiac Rhythm & Heart Failure (CRHF) market increases investor confidence in the Medtronic (MDT) stock.